Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Table 2

Detailed summary of romiplostim dosing schedule.

Parameter	Case #1	Case #2	Case #3
Romiplostim started (postdiagnosis)	3 years (2015)	2 years	3 years
Trial 1
Dose	500 µg	100 µg	75 µg
Frequency	Weekly	Weekly	Weekly
Duration	53 weeks	38 weeks	94 weeks
Platelet range (× 10^9/L)	31–722	35–221	42–595
Trial 2
Dose	250 µg	250 µg	75 µg
Frequency	Biweekly	Biweekly	Biweekly
Duration	11 weeks	131 weeks	20 weeks
Platelet range (× 10^9/L)	86–454	40–129	217–922
Trial 3
Dose	500 µg	—	75 µg
Frequency	Weekly	—	Triweekly
Duration	42 weeks	—	12 weeks
Platelet range (× 10^9/L)	31–1277	—	321–625
Current ITP status	Stable	Partial remission	Complete remission

On weekly dosing of romiplostim 230 µg.